Index

Adenoma-carcinoma sequence, genetic basis for the, 36–37
Adenomatosis polyposis coli (APC), 45–58, 187, 202, 207
  β-catenin pathway, 45–48
  β-catenin /Wnt pathway, 68–69
  and migration, 48
  role of, in CRC carcinogenesis, 37–38
Adjuvant chemotherapy for CRC, 159–167
AKT proto-oncogene, 246
Analytical epidemiology, 5–16
Angiogenesis, 70
Anti-EGFR monoclonal antibodies, 229–233
Antigen
  non-specific immunotherapy, 189–190
  specific immunotherapy, 190–194
Anti-idiotypic antibody vaccines, 193–194
Antisense oligonucleotide therapy, 218
Anti-tumour immune responses, 181–82
APC *see* Adenomatous polyposis coli
Apoptosis, 70
  signalling pathways, 245–248
Ashkenazi Jews, 63
Axin gene, 51–52

Bacterial vectors for gene therapy, 219
Barium enema, 77, 102
Bcl-2 antisense (G3139), 245
β-catenin/
  APC pathway, 45–48
  E-cadherin complex, 48–51
  Wnt/ACP, 68–69
Bodmer WF *see* **Fearnhead NS**
Body mass index, physical activity and energy intake – epidemiology of, 6–8
Boyle P & Leon ME: Epidemiology of colorectal cancer, 1–25
Buda A & Pignatelli M: Genetics – cellular basis, 45–58

Cancer-testis antigens, 184
Capecitabine, 166, 169
Carcino-embryonic antigen (CEA), 66, 80, 96, 185, 190–194, 206–208, 213, 220
  in cancer vaccines, 206–208
  levels, 241
  transfer of, and co-stimulatory molecules, B7.1, 207–208
Catenins, 45–58
Celecoxib, a cyclo-oxygenase-2 (COX-2) inhibitor, 30
Cell adhesion recognition, 70
Cerundolo V *see* **Smith CL**
Cetuximab (C225), 230–232, 246
Chau I & Cunningham D: Chemotherapy in colorectal cancer: new options and new challenges, 159–180
Chemoprevention, prospects for, 17–19
CRC *see* colorectal cancer
Chemotherapy in colorectal cancer: new options and new challenges: **Chau I & Cunningham D**, 159–180
Chen M-J *see* **Palmer DH**
Child-Pugh classification, 129
Chimeric monoclonal antibodies, 230–232
CI-1033, 239
Clinicopathological prognostic factors, 65–66
Colonoscopy, 77, 102
Computed tomography (CT), 102, 105–106
Concerted Action Polyp Prevention (CAPP), 33
Congenital hypertrophy of the retinal pigment epithelium (CHRPE), 28–29
Cost effectiveness of screening, 79
COX-2 *see* Cyclo-oxygenase-2
Cryotherapy, 135–136
CT colography (virtual colonoscopy), 77, 102
Cunningham D *see* **Chau I**
Cyclo-oxygenase-2 (COX-2) inhibitors, 18–19, 30
Cytokines to stimulate T-cell response, 204–206
Cytosine deaminase(CD)/5-fluorocytosine, 211–212

de Bono JS & Rowinsky EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma, 227–254
Denaturing gradient gel electrophoresis (DGGE), 30, 32

© The British Council 2002

Dendritic cells, 191–191
Dietary and nutritional practice – epidemiology of, 8–14
DNA mismatch repair pathway, 69
Dorudi S, Steele RJC & McArdle CS: Surgery for colorectal cancer, 101–118
Dukes' staging, predictive and prognostic factors, 61, 78
Dulphy N *see* **Smith CL**
Dysplasia-associated lesion or mass (DALM), 40

E-cadherin/β-catenin complex, 48–51
Edrocolomab (Panorex®), 167, 198–199
EGFR *see* Epidermal growth factor receptor
EKB-569, 240
Elective surgery for
  colon cancer, 103
  rectal cancer, 103–106
Endoluminal ultrasound (EUS), 104–105
Endorectal ultrasound, 86–87
Energy intake, physical activity and body mass – epidemiology of, 6–8
Eniuracil, 170–171
Enzyme prodrug systems, 210–213
Ep-cam, 185, 198, 249
Epidemiology of colorectal cancer: **Boyle P & Leon ME**, 1–25
Epidermal growth factor (EGF), 51, 52
  receptor (EGFR)
    family, 185
    therapeutics targeting, 228–240
Epigenetic events in colorectal carcinogenesis, 40

Faecal occult blood tests (FOBT), 77–78
Familial adenomatous polyposis coli (FAP), 27, 28–30, 63, 68, 78
Familial juvenile polyposis, 28, 31
Farnesyltransferase (FTase) inhibitors, 241–242
Fearnhead NS, Wilding JL & Bodmer WF: Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis, 27–43
Flexible sigmoidoscopy, 76–77, 102
Fluorochrome-labelled tetramers, 187–189
Fluoropyrimidines, 159, 169–171
5-Fluorouracil (5-FU), 246
  and leucovorin (LV), 159–180
Follow-up postoperative strategies, 114
Fully humanized monoclonal antibodies, 232–233

Ganciclovir, 211
Gene therapy challenges for improving, 219–221
Gene therapy for colorectal cancer: **Palmer DH, Chen M-J & Kerr DJ**, 201–225
Gene-directed enzyme prodrug system (GDEPT), 210–213
Genetic screening for colorectal cancer or multiple adenomas, 35
Genetic testing for inherited syndromes of colorectal cancer, 34
Genetically modified oncolytic virus therapy, 213–217
Genetics – cellular basis: **Buda A & Pignatelli M**, 45–58
Genetics of colorectal cancer: hereditary aspects and overview of colorectal tumorigenesis: **Fearnhead NS, Wilding JL & Bodmer WF**, 27–43
Genomic instability and mutation rate, 38–39
Gleeson FV *see* **Saunders TH**
Glimelius B: Radiotherapy in rectal cancer, 141–157
GW5572016, 238

Hamartomatous polyps, 28, 54
Hepatic arterial infusion (HAI), 138
Hepatic metastases, 90–93
Hepatocyte growth factor (HGF), 51
HER2/*neu*, 185, 193
Hereditary
  aspects and overview of colorectal tumorigenesis, 27–43
  gastric cancer, 28
  non-polyposis colorectal cancer (HNPCC), 27, 28, 31–3363, 67, 68, 78
Herpes simplex virus (HSV), 211, 213
  thymidine kinase (TK)/ganciclovir, 211
Hole DJ *see* **McArdle CS**
Hormone replacement therapy (HRT), epidemiology of, 15–16
Human anti-chimeric antibodies (HACA), 230, 234
Human anti-murine antibodies (HAMA), 83
Human epithelial mucins, 185
Human leukocyte antigen (HLA) to stimulate T-cell response, 203–204

Imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up, 81–99
Immune
stimulation (immunogene therapy), 202
system, 182–184
Immunogene therapy (immune stimulation), 202
Immunomonitoring, 187–189
Immunotherapy of colorectal cancer: **Smith CL, Dulphy N, Salio M & Cerundolo V**, 181–200
Immunotherapy
antigen non-specific, 189–190
antigen-specific, 190–194
'tumour escape': an obstacle to?, 194
Indocyanin green (ICG) retention test for liver function, 129
Inextirpable rectal cancer, radiotherapy in, 150–152
Inherited predisposition to colorectal cancer, 27–35
Irinotecan, 159, 166, 171–172, 246
Irinotecan/oxaliplatin, 174–176

Juvenile polyposis (SMAD4 mutation), 63

Kerr DJ *see* **Palmer DH**

Laparoscopic surgery for colorectal cancer, 112–113
Leon ME *see* **Boyle P**
Leucovorin (LV) and 5-FU, 159–180
Liver metastases from CRC, surgery of, 127–140
decreasing postoperative recurrence, 137–138
Liver resection for colorectal metastases, pre-operative chemotherapy, 136–137
Local excision of colorectal cancer, 111–112
Locally recurrent tumours, 94–97
Lymph nodes and extra hepatic spread, 87–90
Lytic enzyme production, 70–71

Magnetic resonance imaging (MRI), 102
and rectal cancer staging, 106
use with PET and radioimmunoscintigraphy for imaging CRC: primary staging and follow-up, 81–99
Malignant obstruction, management of, 113–114
Matrix metalloproteinase (MMP), 70–71
Maughan NJ & Quirke P: Pathology – a molecular prognostic approach, 59–74
McArdle CS & Hole DJ: Outcome following surgery for colorectal cancer, 119–125
McArdle CS *see also* **Dorudi S**
Mendes Ribeiro HK *see* **Saunders TH**
Metalloproteinase matrilysin (MMP-7), 52
Microsatellite instability (MSI), 32, 39, 64, 67–69, 186–187
Mitogen activated protein kinase (MAPK) pathways, 242
Molecular predictive factors, 71
Molecular prognostic approach to CRC, 59–74
Monoclonal antibodies
anti-EGFR, 229–233
chimeric , 230–232
fully humanized, 232–233
MRI *see* Magnetic resonance imaging
MUC-1, 185
Mutant gene correction, 208–210
Mutation rate and genomic instability, 38–39
Myeloprotective gene transfer in conjunction with chemotherapy, 217–218

New targets and future directions, 71–72
New techniques for imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up: **Saunders TH, Mendes Ribeiro HK & Gleeson FV**, 81–99
NF-κB, inhibition of, 246–248
Nitroreductase/CB 1954, 212–213
Non-steroidal anti-inflammatory drugs (NSAIDs), 17–18
Nordlinger B *see* **Penna C**
Nutritional and dietary practices – epidemiology of, 8–14

Oncolytic virus therapy, genetically modified, 213–217
adenovirus, 214–215
OSI-774 (Tarceva®), 237–238

Outcome following surgery for colorectal cancer: **McArdle CS & Hole DJ**, 119–125
Outcome of liver resection for colorectal metastases, 130–134
Over-expressed antigens, 184–185
Oxaliplatin, 159, 167, 172–174, 246
/irinotecan, 174–176

P13 kinase-Akt pathway, 241
p53, 186
tumour suppressor gene correction, 208–209
Palmer DH, Chen M-J & Kerr DJ: Gene therapy for colorectal cancer, 201–225
Pathology – a molecular prognostic approach: **Maughan NJ & Quirke P**, 59–74
Penna C & Nordlinger B: Surgery of liver metastases from colorectal cancer – new promises, 127–140
Peutz Jegher's syndrome, 28, 30
LKB1 mutation, 63
Phenylketonuria (PKU), 35
Physical activity, body mass index and energy intake – epidemiology of, 6–8
Pigr atelli M *see* **Buda A**
PKI 166, 238
Polyposis syndromes, 27, 28, 30–31
Portal vein embolization, 135
Positron emission tomography (PET), MRI and radioimmunoscintigraphy for imaging CRC: primary staging and follow-up, 81–99
Predictive and prognostic factors for CRC, 59–74
Pre-operative preparation, 102
Primary staging, 84–87
Prodrug activation, 210–213
Prognostic (molecular) approach to CRC, 59–74
Proliferation/cell cycle, 70
Protein truncation test (PTT), 30, 32

Radical (curative) surgery for rectal cancer, 106–111
Radiofrequency ablation (RFA), 135–136
Radioimmunoscintigraphy, MRI and PET for imaging CRC: primary staging and follow-up, 81–99
Radiotherapy
(adjuvant) in rectal cancer, 110–111
in rectal cancer: **Glimelius B**, 141–157
Raf-MEK-Erk pathway, 241
Raltitrexed, 159, 176
ras proto-oncogenes, 187
ras signal transduction, targeting, 240–242
Receptor tyrosine kinase inhibitors (RTK), 233–238
Recombinant plasmid DNA and viral vectors, 190–191
Rectal cancer
radical (curative) surgery for, 106–111
radio(chemo)therapy in, 141–157
role of adjuvant radiotherapy in, 110–111
Recurence of colorectal metastases, reduction of, 138–139
Replication error (RER$^+$), 32, 39
Risk, spectrum of, for colorectal cancer, 78
Rowinsky EK *see* **de Bono JS**

Salio M *see* **Smith CL**
Saunders TH, Mendes Ribeiro HK & Gleeson FV: New techniques for imaging colorectal cancer: the use of MRI, PET and radioimmunoscintigraphy for primary staging and follow-up, 81–99
Screening for colorectal cancer: **Scholefield JH**, 75–80
Screening, 19–20
Screening, genetic, 35
Serine-threonine kinase Akt, 246
Signal transduction, therapeutics targeting, for patients with colorectal carcinoma, 227–254
Single strand conformational polymorphism (SSCP), 30, 32
Smith CL, Dulphy N, Salio M & Cerundolo V: Immunotherapy of colorectal cancer, 181–200
Sphincter preservation, radio(chemo)therapy in rectal cancer, 152–153
Staging of rectal cancer, 103–104
Staging, TNM, of colorectal cancer, 84
Steele RJC *see* **Dorudi S**
Subtyping colorectal cancer, 63–65
Suicide gene therapy, 210–213
Surgery for colorectal cancer, outcome following, 119–125
Surgery for colorectal cancer: **Dorudi S, Steele RJC & McArdle CS**, 101–118
Surgery of liver metastases from colorectal cancer – new promises: **Penna C & Nordlinger B**, 127–140
Symptom questionnaires, 76

Targeting
mitogen activated protein kinase pathways, 242
ras signal transduction, 240–242
Raf-1 signalling, 242–244
T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors, 51
Tcf4/Wingless pathway, 68–69
Tegafur and uracil (UFT), 166–167, 169–170
Therapeutic strategies, 189–194
Therapeutics targeting signal transduction for patients with colorectal carcinoma, de Bono JS & Rowinsky EK, 227–254
TNM staging of colorectal cancer, 84
Tobacco smoking and colorectal cancer risk, 14–15
Trail (TNF related apoptosis inducing ligand) treceptors, targeting, 248
Transanal endoscopic microsurgery (TEM), 111–112
Transcriptionally active drugs, 218
Transforming growth factor β (TGF-β), 54–55
TGF-β/SMAD2 and SMAD4 pathway, 69
receptor II (TGF-βR-II), 186–187
Tumorigenesis, overview of colorectal, 27–43
Tumour antigens, 184–187
Tyrosine kinase,
receptor, inhibitors, 233–238
irreversible inhibitors, 238–240

Ulcerative colitis associated colorectal carcinoma (UCACRC), 40
Ultrasound
endoluminal (EUS), 104–105
endorectal, 86–87
Uracil and tegafur (UFT) oral, 166–167, 169–170
Uracil plus LV, 166–167
Urokinase-type plasminogen activator receptor (uPAR), 52

Vaccines, anti-idiotypic antibody, 193–194
Vaccines (cancer),
carcino-embryonic antigen (CEA) in, 206–208
development and delivery, 181–200
Variable number of tandem repeat (VNTR) regions, 185
Vascular endothelial growth factor (VEGF), 52, 70, 72
Virus-directed enzyme prodrug therapy (VDEPT), 210–213

Wilding JL *see* **Fearnhead NS**
Wingless/Tcf4 pathway, 68–69
Wingless/Wnt signalling pathway, 51–54
Wnt/APC/β-catenin pathway, 68–69

ZD 1839 (Iresa®), 233–237